A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

计划入组 600 人 · 首次发布于 2024 年 5 月 17 日

Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer

首次发布于 2021 年 9 月 16 日

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer

计划入组 37 人 · 首次发布于 2018 年 11 月 1 日

EGFR inhibitors (non-small cell lung cancer)

GSK-2302032A

GFPT2 inhibitors (non-small-cell lung cancer)

ADDARIO LUNG CANCER MEDICAL INSTITUTE

United States

European Lung Cancer Working Party

Belgium

Summit Therapeutics Inc.

United States

ORIC Pharmaceuticals Gains 36% Following Positive Cancer Data and Strategic Partnerships

PAPILLON Final Analysis: Amivantamab Plus Chemotherapy Delivers 34.3-Month Median OS in EGFR Exon 20 Insertion NSCLC

J&J's Rybrevant Shows 45% Response Rate in Head and Neck Cancer, Doubling Standard of Care